Characterization of on-target adverse events caused by TRK inhibitor therapy
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Purpose. The TRK pathway controls appetite, balance, and pain sensitivity. While these functions are reflected in the on-target adverse effects (AEs) observed with TRK inhibition, these AEs remain under-recognized, and pain upon drug withdrawal has not previously been reported. As TRK inhibitors are approved by multiple regulatory agencies for TRK or ROS1 fusion-positive cancers, characterizing these AEs and corresponding management strategies is crucial. Methods. Patients with advanced or unresectable solid tumors treated with a TRK inhibitor were retrospectively identified in a search of clinical databases. Among these patients, the frequency, severity, duration, and management outcomes of AEs including weight gain, dizziness or ataxia, and withdrawal pain were characterized. Results. Ninety-six patients with 15 unique cancer histologies treated with a TRK inhibitor were identified. Weight gain was observed in 53% (95% CI, 43%-62%) of patients and increased with time on TRK inhibition. Pharmacologic intervention, most commonly with GLP-1 analogs or metformin, appeared to result in stabilization or loss of weight. Dizziness, with or without ataxia, was observed in 41% (95% CI, 31%-51%) of patients with a median time to onset of 2 weeks (range, 3 days to 16 months). TRK inhibitor dose reduction was the most effective intervention for dizziness. Pain upon temporary or permanent TRK inhibitor discontinuation was observed in 35% (95% CI, 24%-46%) of patients; this was more common with longer TRK inhibitor use. TRK inhibitor re-initiation was the most effective intervention for withdrawal pain. Conclusions. TRK inhibition-related AEs including weight gain, dizziness, and withdrawal pain occur in a substantial proportion of patients receiving TRK inhibitors. This safety profile is unique relative to other anticancer therapies and warrants careful monitoring. These on-target toxicities are manageable with pharmacologic intervention and dose modification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824 · cited 4×
“While the overall side-effect profile of TRK inhibitors has been reported in prospective trials[3, 18], further characterizing the adverse events that are likely emerge secondary to TRK inhibition and defining potential management strategies for these adverse events is an unmet need.”
BackgroundInfluentialSelf-citationDoebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790 · cited 1×
“While the overall side-effect profile of TRK inhibitors has been reported in prospective trials[3, 18], further characterizing the adverse events that are likely emerge secondary to TRK inhibition and defining potential management strategies for these adverse events is an unmet need.”
BackgroundSelf-citationPharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347 · cited 1×
“FDA-approved medications for weight management include phentermine-topiramate, liraglutide, naltrexone-bupropion, lorcaserin, and orlistat (Table 2) [24, 25].”
BackgroundDrilon, A., Ou, S.-H. I., Cho, B. C., Kim, D.-W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M.-J., Camidge, D. R., Nguyen, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0484 · Cited by 504
Self-citation
Cited by
ROS1-dependent cancers — biology, diagnostics and therapeutics
Drilon, A., Jenkins, C., Iyer, S., Schoenfeld, A., Keddy, C., & Davare, M. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0408-9 · Cited by 294
Self-citationRepotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
Drilon, A., Camidge, D. R., Lin, J. J., Kim, S.-W., Solomon, B. J., Dziadziuszko, R., Besse, B., Goto, K., de Langen, A. J., Wolf, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2302299 · Cited by 240
Self-citationLong-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
Drilon, A., Chiu, C.-H., Fan, Y., Cho, B. C., Lu, S., Ahn, M.-J., Krebs, M. G., Liu, S. V., John, T., Otterson, G. A., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100332 · Cited by 113
“These were not unexpected given that entrectinib is a potent inhibitor of TRKA, TRKB, and TRKC, which maintain important neurologic roles in adults, including the regulation of balance, appetite (the most common grade 3 TRAE in this data set was weight gain) and pain thresholds.(28) A late onset of increased creatinin…”
ResultSelf-citationDrilon, A., Horan, J. C., Tangpeerachaikul, A., Besse, B., Ou, S.-H. I., Gadgeel, S. M., Camidge, D. R., van der Wekken, A. J., Nguyen-Phuong, L., Acker, A., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0968 · Cited by 52
Self-citationLi, W., Xiong, A., Yang, N., Fan, H., Yu, Q., Zhao, Y., Wang, Y., Meng, X., Wu, J., Wang, Z., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00731 · Cited by 40
Metadata
- Authors
- Liu, D., Flory, J., Lin, A., Offin, M., Falcon, C. J., Murciano-Goroff, Y. R., Rosen, E., Guo, R., Basu, E., Li, B. T., Harding, J. J., Iyer, G., Jhaveri, K., Gounder, M. M., Shukla, N. N., Roberts, S. S., Glade-Bender, J., Kaplanis, L., Schram, A., Hyman, D. M., & Drilon, A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 31
- Issue
- 9
- Pages
- 1207-1215
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3024986856
- Cited by
- 95
- References
- 4
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.